604 Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1–6 mouse models of hepatocellular carcinoma

• Aaron Morris,
• Arthur Krieg,
• Evan Walters,
• Bassel Akache,
• Michael McCluskie

Affiliations

Aaron Morris

1Checkmate Pharmaceuticals, Cambridge, MA, USA

Arthur Krieg

1Checkmate Pharmaceuticals, Cambridge, MA, USA

Evan Walters

1Checkmate Pharmaceuticals, Cambridge, MA, USA

Bassel Akache

2National Research Council Canada, Ottawa, Canada

Michael McCluskie

2National Research Council Canada, Ottawa, Canada